Exicure, Inc. (XCUR) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2018

Exicure, Inc.

CIK: 1698530 Ticker: XCUR

Exhibit 99.1


Exicure, Inc. Reports Full Year 2018 Financial Results and Corporate Progress

Completed Phase 1 clinical trials of two drugs and began public trading

SKOKIE, Ill - March 8, 2019
- Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today reported full year financial results for the year ended December 31, 2018 and provided an update on corporate progress.
“We’re very proud of our achievements on each of our strategic priorities for 2018,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “We drove two programs through Phase 1 clinical trials while laying the foundation for expanding our pipeline in neurology, rare dermatology, ophthalmology and gastroenterology. We also strengthened the management of our company and our access to capital. In the coming year, we expect to execute and advance our ongoing clinical programs, while expanding into new therapeutic areas,” Giljohann concluded.
Corporate Progress
Key achievements for Exicure during 2018 include:
Completed the Phase 1 clinical trial of AST-008, a TLR9 agonist for immuno-oncology applications showing activation of the immune system and robust cellular response.
Completed a successful Phase 1 clinical trial of XCUR17 showing clinical effect in patients with psoriasis
Demonstrated, in preclinical animal models, superior bio-distribution and prolonged survival when administering nusinersen in SNA format versus nusinersen in linear format
Strengthened management team with addition of Dr. Matthias Schroff as Chief Operating Officer
Commenced public trading on the OTCQB market
Completed $22.0 million financing in August of 2018 at $4.50/share

Pipeline Updates
AST-008: AST-008 is an SNA consisting of toll-like receptor 9, or TLR9, agonists designed for immuno-oncology applications. The company began subject dosing of AST-008 in a Phase 1 clinical trial during the fourth quarter 2017 and the trial completed in September of 2018. AST-008 was shown to be safe and tolerable in all subjects, with no serious adverse events and no dose limiting toxicity. During the fourth quarter of 2018 the FDA opened the IND for AST-008 and informed the Company that our proposed Phase 1b/2 trial may proceed. During early 2019 we opened four clinical sites and began dosing and recruiting patients in that trial.
XCUR17: XCUR17 is an antisense SNA that targets the mRNA encoding IL-17RA, a protein that is considered essential in the initiation and maintenance of psoriasis. In the fourth quarter of 2018 we reported results from the Phase 1 trial of XCUR17. Of the twenty-one treated patients, eleven treated with the highest strength XCUR17 gel were observed to have a reduction in redness and improvement in healing as determined by blinded physician assessments. Further, the highest strength XCUR17 gel showed a statistically significant improvement in psoriasis symptoms versus the vehicle gel. By comparison, seventeen of the twenty-one patients treated with the positive comparator showed a clinical response, while four patients treated with the placebo vehicle had a clinical response.


The following information was filed by Exicure, Inc. (XCUR) on Friday, March 8, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Exicure, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Exicure, Inc..


Assess how Exicure, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Exicure, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Changes In Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Narrative (Details)
Commitments And Contingencies - Schedule Of Future Minimum Rental Payments (Details)
Commitments And Contingencies - Schedule Of Rent Expense (Details)
Debt (Tables)
Debt - Narrative (Details)
Debt - Principal Maturities Of Long-Term Debt (Details)
Defined Contribution Plan
Defined Contribution Plan - Narrative (Details)
Description Of Business And Basis Of Presentation
Description Of Business And Basis Of Presentation - Description Of Business (Details)
Description Of Business And Basis Of Presentation - Schedule Of Error Corrections (Details)
Equity-Based Compensation
Equity-Based Compensation (Tables)
Equity-Based Compensation - Assumptions Used For Fair Value Measurement (Details)
Equity-Based Compensation - Fair Value Of Underlying Common Stock And Exercise Price Of Stock Options (Details)
Equity-Based Compensation - Narrative (Details)
Equity-Based Compensation - Schedule Of Compensation Expense (Details)
Equity-Based Compensation - Schedule Of Stock Options Rollforward (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Narrative (Details)
Fair Value Measurements - Reconciliation Of Liabilities Measured At Fair Value On A Recurring Basis (Details)
Fair Value Measurements - Schedule Of Assumptions Used To Estimate Fair Value Of Warrant Liability (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Deferred Tax Assets And Liabilities (Details)
Income Taxes - Effective Income Tax Rate Reconciliation (Details)
Income Taxes - Narrative (Details)
Loss Per Common Share
Loss Per Common Share (Tables)
Loss Per Common Share - Antidilutive Securities (Details)
Loss Per Common Share - Computation Of Earnings Per Share (Details)
Purdue Collaboration
Purdue Collaboration (Details)
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (Tables)
Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Details)
Related-Party Transactions
Related-Party Transactions (Tables)
Related-Party Transactions - Narrative (Details)
Related-Party Transactions - Schedule Of Revenue From Related Party (Details)
Significant Accounting Policies
Significant Accounting Policies (Policies)
Significant Accounting Policies - Concentrations Of Credit Risk And Other Risks And Uncertainties (Details)
Significant Accounting Policies - Property And Equipment (Details)
Significant Accounting Policies - Recently Adopted Accounting Pronouncements (Details)
Significant Accounting Policies - Segments And Geographic Information (Details)
Stockholders' Equity
Stockholders' Equity - Common Stock Warrants (Details)
Stockholders' Equity - Current Capitalization (Details)
Stockholders' Equity - Private Placement Post-Merger And Registration Rights (Details)
Stockholders' Equity - The Merger And Other - Prior To The Merger (Details)
Subsequent Events
Subsequent Events - Narrative (Details)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Supplemental Balance Sheet Information - Accrued Expense And Other Current Liabilities (Details)
Supplemental Balance Sheet Information - Property And Equipment, Net (Details)
Ticker: XCUR
CIK: 1698530
Form Type: 10-K Annual Report
Accession Number: 0001698530-19-000015
Submitted to the SEC: Fri Mar 08 2019 5:21:12 PM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: